INTRODUCTION {#sec1-1}
============

Holt--Oram syndrome (HOS) is a rare autosomal dominant condition that was first identified in a family with generational anomalies of the upper extremity, arrhythmias, and suspicion of atrial septum defects.\[[@ref1]\] Few cases of malignancy have been documented previously in association with this syndrome, and to the best of our knowledge, we document the first case of B precursor acute lymphoblastic leukemia (B-ALL) in a patient with HOS. We further document the challenges faced addressing the side effects of the chemotherapeutic regimen for a patient with congenital conduction anomalies.

CASE REPORT {#sec1-2}
===========

A 12-year-old female with clinically diagnosed HOS status postatrial septal defect and ventricular septal defect repair at 3 months of life and known first-degree heart block was admitted to Rush University Medical Center for newly diagnosed B-ALL. She presented to Pediatric Cardiology Clinic for transient, position-dependent presyncopal episodes over a 2-month period. A 30-day event monitor was placed and did not reveal any heart block during a syncopal episode. During this period, she also presented to her primary care provider for pallor. A complete blood count revealed thrombocytopenia and anemia. The patient was subsequently admitted due to concern for leukemia on further workup \[[Table 1](#T1){ref-type="table"}\]. Her physical examination was remarkable for bilateral submandibular and anterior cervical lymphadenopathy, a systolic murmur, hepatosplenomegaly, pallor, and absence of thumbs bilaterally.

###### 

Baseline characteristics and laboratories at the time of admission

  Baseline characteristics   Result
  -------------------------- ---------------
  Height                     154.7 cm
  Weight                     52.1 kg
  BSA                        1.5 m^2^
  WBC                        14.9 K/µL
  Hemoglobin                 6.7 g/dL
  Platelet                   68 K/µL
  Neutrophil                 940 K/µL
  LDH                        304 U/L
  Uric acid                  6.7 mg/dL
  Folic acid                 5.2 ng/mL
  Ferritin                   490 ng/mL
  Chest X-ray                normal
  PR interval                192 ms
  QT/QTc                     406 ms/477 ms

BSA: Body surface area, WBC: White blood cell, K: 1000, U: Units, LDH: Lactate dehydrogenase

On the day of admission, hospital day 0 (HD0), a baseline echocardiogram revealed normal function and no residual septal defects. A baseline electrocardiogram (ECG) demonstrated a normal sinus rhythm with first-degree AV block and a QTc of 479 ms \[[Figure 1a](#F1){ref-type="fig"}\]. On HD1, a bone marrow biopsy confirmed the diagnosis of B-ALL. On HD3, intrathecal cytarabine was administered for day of induction 1 (DOI\#1). She was given a single dose of intravenous vincristine and daunorubicin followed by oral prednisone after recovery from anesthesia. During DOI\#2, she was noted to have a heart rate (HR) between 40 and 50 bpm even while awake after the fourth dose of steroid. She was asymptomatic with normal orthostatic blood pressure measurements, normal electrolytes, and a 12-lead ECG with sinus bradycardia and first-degree AV block \[[Figure 1b](#F1){ref-type="fig"}\]. A 24-h Holter monitor was placed on DOI\#3 and revealed an average HR of 50 bpm (range: 36--81 bpm). The patient experienced significant nausea during induction that was only responsive to ondansetron. She underwent continuous monitoring with daily ECGs without issue. She was asymptomatic from the bradycardia throughout the hospitalization and was discharged on DOI\#5 with a HR 56 bpm. At follow-up visits, her HR range was predominantly within normal limits. On subsequent admissions, the lowest HR documented was 42 bpm with HR predominantly above 50 bpm.

![(a) Baseline electrocardiogram on the day of admission demonstrating a prolonged PR interval and mild QTc prolongation. (b) Electrocardiogram obtained during bradycardic episodes demonstrating sinus bradycardia, prolonged PR interval, and no QTc prolongation](APC-13-241-g001){#F1}

DISCUSSION {#sec1-3}
==========

While leukemia is the most common form of cancer in pediatric patients, no cases have been documented in a patient with HOS.\[[@ref2]\] To the best of our knowledge, HOS in association with malignancy is rare, with six cases documented in the literature \[[Table 2](#T2){ref-type="table"}\].\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8]\] From these documented cases, only Yoshihara *et al*. reported challenges and limitations before chemotherapy treatment due to concern for side effects in the context of acute heart failure.

###### 

The case reports previously published on patients with Holt-Oram syndrome and identified malignancy

  Age/sex           Malignancy                Skeletal anomalies                                                                                                                                                                                                           Heart defect                                        References
  ----------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------
  16 years/female   Adenocarcinoma            Short upper appendages with small scapulae, humeri, radii, and phalanges                                                                                                                                                     Atrial septal defect\*                              Rabinowitz et al. 1971
  24 years/male     Lymphosarcoma             Left arm 10 cm shorter than the right. Deformity of the end of the humerus with the congenital subluxation of the elbow; fusion of metacarpal bones; absence of left thumb, fifth finger, first and fifth metacarpal bones   Atrial septal defect                                Nik-Akhtar et al. 1974
  23 years/female   Pheochromocytoma          Bilateral agenesis of radial bone and first finger                                                                                                                                                                           Dextrocardia, single ventricle, pulmonary atresia   Yoshihara et al. 2008
  41 years/male     Adenocarcinoma            Bilateral radial foreshortening, triphalangeal thumbs, digit aplasia                                                                                                                                                         Not reported                                        Aherne et al. 2013
  7 months/female   Nephroblastoma            Bilateral absence of the radial bones; deformed, shortened ulna bones; and bony ankylosis of the elbows                                                                                                                      Ventricular septal defect                           Usang et al. 2016
  31 years/male     Squamous cell carcinoma   Bilateral thumb anomalies                                                                                                                                                                                                    Atrial septal defect                                Rana et al. 2017

The patient HOS and malignancy characteristics are provided when available. \*Patient refused catheterization but had findings consistent with ASD. HOS: Holt-Oram syndrome, ASD: Atrial septal defect

Our patient experienced bradycardia on DOI\#2. We postulated that her bradycardia may have been due to three potential etiologies: first, this was a natural progression of her underlying conduction defect; second, this was an acute change secondary to the oncologic burden; and third, this was chemotherapy-related, specifically steroid-associated bradycardia. The first two theories were contradicted by the fact that the patient\'s resting HR during the portion of the admission before DOI\#1 was within the normal limits (average HR 68 with range 61--97 bpm). This differed significantly from the 24-h Holter monitor completed on DOI\#3 (average HR 50 with range 36--81 bpm). Moreover, the acute onset of the bradycardia without symptoms \[[Figure 2](#F2){ref-type="fig"}\] and the lack of return at follow-up visitsfurther support the theory that this was a response to the initiation of potent steroids. Another potential cause of bradycardia could be attributed to the patient\'s hypervolemic state while undergoing hydration therapy. The patient received other medications during this time; however, the incidence of bradycardia occurred long after their administration.

![Box plot demonstrating heart rate trend during hospitalization. The y-axis is heart rate and x-axis is time based on the day of chemotherapy induction. Horizontal red line indicates steroid administration. Horizontal blue line encompasses the time period when Holter monitor was completed](APC-13-241-g002){#F2}

Corticosteroid-associated bradycardia is a physiologic response first noted in patients with rheumatoid arthritis receiving pulse intravenous methylprednisolone.\[[@ref9]\] There are numerous reports of patients developing this response to receiving pulse steroids for rheumatologic as well as oncologic conditions with one report demonstrating a nadir after 5--10 doses of steroids.\[[@ref10][@ref11][@ref12]\] We speculate that the initiation of high-dose steroids may modulate a bradycardic response through androgen receptors that are not sustained during prolonged exposure. However, further research is needed to elucidate the mechanism. We further summarize that her presyncopal episodes before admission were vasovagal in nature confounded by anemia due to B-ALL.
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